RxDoctor Payments Data

Neirouz Joseph, MD

Family Medicine · Jacksonville, FLNPI 1275686081

Payments from drug & device makers

$6,806in general payments, 2019–2025

Across 307 payments — averaging $22.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$892
  • AstraZeneca$779
  • Lilly USA, LLC$735
  • GSK$559
  • Pfizer$505
  • Amgen$492
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$6,795100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,806 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$123,590
Medicare patients
246
Services billed
1,532

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide68$82,182
OzempicSemaglutide46$51,973
TrulicityDulaglutide12$25,196
JardianceEmpagliflozin23$20,825
EliquisApixaban17$17,489
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$15,114
MyrbetriqMirabegron15$8,765
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr17$8,047
BelsomraSuvorexant16$7,126
Tresiba Flextouch U-100Insulin Degludec14$6,933
Rosuvastatin Calcium270$4,710
Atorvastatin Calcium392$4,351
SynthroidLevothyroxine Sodium37$2,896
Duloxetine Hcl74$2,539
Gabapentin105$2,493

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$735$107,37880 claims
Novo NordiskOzempic$892$51,97346 claims
GSKTrelegy Ellipta, Anoro Ellipta$559$23,16037 claims
Boehringer IngelheimJardiance$245$20,82523 claims
PfizerEliquis$505$17,48917 claims
Astellas Pharma US IncMyrbetriq$326$8,76515 claims
MerckBelsomra$96$7,12616 claims
AbbVieSynthroid$100$2,89637 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →